Silence Therapeutics plc (SLNCF)
OTCMKTS · Delayed Price · Currency is USD
2.210
+1.150 (108.49%)
Jun 15, 2026, 3:05 PM EST
Silence Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.84 | 0.56 | 43.26 | 31.64 | 21.66 | 16.81 | |
Revenue Growth (YoY) | -96.97% | -98.71% | 36.71% | 46.12% | 28.82% | 124.73% |
Cost of Revenue | 0.17 | 0.22 | 11.81 | 12.87 | 13.46 | 10.1 |
Gross Profit | 0.67 | 0.34 | 31.45 | 18.78 | 8.19 | 6.71 |
Selling, General & Admin | 21.69 | 22.34 | 26.88 | 26.22 | 25.68 | 27.09 |
Research & Development | 50.59 | 60.29 | 54.15 | 44.99 | 33.73 | 41.66 |
Operating Expenses | 72.27 | 82.63 | 81.03 | 71.21 | 59.41 | 68.75 |
Operating Income | -71.61 | -82.29 | -49.58 | -52.43 | -51.22 | -62.03 |
Interest Expense | - | - | - | - | - | -0.01 |
Interest & Investment Income | 0.02 | 0.02 | 0.7 | - | - | 0.01 |
Currency Exchange Gain (Loss) | -5.18 | -8.47 | 0.65 | -2.64 | 1.29 | -0.06 |
Other Non Operating Income (Expenses) | 3.07 | 3.47 | 3.77 | 1.8 | 0.28 | - |
EBT Excluding Unusual Items | -73.7 | -87.28 | -44.46 | -53.27 | -49.65 | -62.09 |
Merger & Restructuring Charges | -1.32 | -1.32 | - | - | - | - |
Pretax Income | -75.03 | -88.6 | -44.46 | -53.27 | -49.65 | -62.09 |
Income Tax Expense | 0.01 | 0.01 | 0.85 | 0.96 | 0.69 | -8.73 |
Net Income | -75.04 | -88.61 | -45.31 | -54.23 | -50.33 | -53.36 |
Net Income to Common | -75.04 | -88.61 | -45.31 | -54.23 | -50.33 | -53.36 |
Shares Outstanding (Basic) | 47 | 47 | 46 | 37 | 32 | 30 |
Shares Outstanding (Diluted) | 47 | 47 | 46 | 37 | 32 | 30 |
Shares Change (YoY) | 0.35% | 2.12% | 24.69% | 15.21% | 8.58% | 8.78% |
EPS (Basic) | -1.59 | -1.88 | -0.98 | -1.46 | -1.56 | -1.80 |
EPS (Diluted) | -1.61 | -1.88 | -0.98 | -1.46 | -1.56 | -1.80 |
Free Cash Flow | -65.62 | -62.33 | -67.85 | -49.52 | -57.22 | 7.44 |
Free Cash Flow Per Share | -1.39 | -1.32 | -1.47 | -1.33 | -1.78 | 0.25 |
Gross Margin | 79.50% | 61.54% | 72.70% | 59.34% | 37.83% | 39.94% |
Operating Margin | -8534.68% | -14720.93% | -114.62% | -165.70% | -236.53% | -369.02% |
Profit Margin | -8943.86% | -15851.88% | -104.74% | -171.37% | -232.44% | -317.44% |
Free Cash Flow Margin | -7820.74% | -11149.55% | -156.85% | -156.49% | -264.22% | 44.26% |
EBITDA | -71.08 | -81.74 | -48.99 | -51.81 | -50.62 | -61.69 |
EBITDA Margin | - | - | -113.25% | -163.74% | -233.78% | - |
D&A For EBITDA | 0.52 | 0.56 | 0.59 | 0.62 | 0.6 | 0.34 |
EBIT | -71.61 | -82.29 | -49.58 | -52.43 | -51.22 | -62.03 |
EBIT Margin | - | - | -114.62% | -165.70% | -236.53% | - |